Avomeen has appointed Alex Garner as its new Director of Formulation and Clinical Trial Manufacturing. Garner will work to further expand and strengthen Avomeen’s formulation and clinical trial manufacturing capabilities to support biopharmaceutical clients whose product portfolios include both small- and large-molecule therapies.

Garner joins the company from Avomeen with more than a decade of experience in the CDMO and biopharmaceutical industries. Most recently, he served as Pharmaceutical Development Scientist II at Metrics Contract Services, a Division of Mayne Pharma Inc. There, he supervised manufacturing specialists and scientists, while also serving as the primary of point of contact with clients regarding pharmaceutical development and clinical trial manufacturing related activities. Prior to this, he held scientist positions at Patheon and Metrics, Inc./Mayne Pharma.

Throughout his career, Garner has served as a principal investigator for journal articles and has been a featured presenter at industry conferences. He has also contributed to multiple peer-reviewed publications and instrument-specific certifications through Waters Corporation.

“Alex brings a wealth of knowledge and expertise in chemistry, manufacturing, and controls (CMC) strategy, process and formulation development, clinical trial batch manufacturing, and packing and documentation,” said Mark Harvill, Avomeen Chief Executive Officer. “His leadership, along with his extensive CMC and formulation knowledge, will help us expand this business segment to ensure Avomeen is positioned to provide comprehensive, full-service formulation and manufacturing support to clients in both small- and large-molecule development.”